CytomX Therapeutics, Inc. (NASDAQ:CTMX) Sees Large Decrease in Short Interest

CytomX Therapeutics, Inc. (NASDAQ:CTMX) saw a large decline in short interest in the month of December. As of December 31st, there was short interest totalling 4,800,000 shares, a decline of 13.4% from the December 15th total of 5,540,000 shares. Based on an average daily trading volume, of 1,230,000 shares, the days-to-cover ratio is presently 3.9 days.

Analyst Ratings Changes

Separately, HC Wainwright restated a “neutral” rating on shares of CytomX Therapeutics in a research report on Tuesday, January 7th. Four investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $5.77.

CytomX Therapeutics Stock Down 0.8 %

Shares of CTMX traded down $0.01 on Friday, hitting $0.84. The company’s stock had a trading volume of 620,234 shares, compared to its average volume of 992,394. The firm’s fifty day moving average price is $1.04 and its 200-day moving average price is $1.15. CytomX Therapeutics has a fifty-two week low of $0.79 and a fifty-two week high of $5.85. The firm has a market capitalization of $65.74 million, a price-to-earnings ratio of 4.94 and a beta of 1.03.

CytomX Therapeutics (NASDAQ:CTMX) last issued its quarterly earnings data on Thursday, November 7th. The biotechnology company reported $0.07 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.16) by $0.23. CytomX Therapeutics had a negative return on equity of 41.47% and a net margin of 10.96%. The business had revenue of $33.43 million during the quarter, compared to analyst estimates of $18.92 million. During the same period in the previous year, the firm earned $0.04 EPS. As a group, equities analysts predict that CytomX Therapeutics will post -0.05 earnings per share for the current fiscal year.

Institutional Investors Weigh In On CytomX Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Assenagon Asset Management S.A. raised its stake in CytomX Therapeutics by 32.8% in the 3rd quarter. Assenagon Asset Management S.A. now owns 1,644,168 shares of the biotechnology company’s stock valued at $1,940,000 after acquiring an additional 405,669 shares during the period. Sei Investments Co. bought a new stake in CytomX Therapeutics in the 2nd quarter valued at $467,000. Virtu Financial LLC bought a new stake in CytomX Therapeutics in the 3rd quarter valued at $104,000. Congress Park Capital LLC raised its stake in CytomX Therapeutics by 5.4% in the 3rd quarter. Congress Park Capital LLC now owns 1,216,008 shares of the biotechnology company’s stock valued at $1,435,000 after acquiring an additional 62,788 shares during the period. Finally, XTX Topco Ltd raised its stake in CytomX Therapeutics by 382.6% in the 2nd quarter. XTX Topco Ltd now owns 60,586 shares of the biotechnology company’s stock valued at $74,000 after acquiring an additional 48,033 shares during the period. Institutional investors own 67.77% of the company’s stock.

About CytomX Therapeutics

CytomX Therapeutics, Inc, an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology.